

CARDIOL THERAPEUTICS INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026

MANAGEMENT'S DISCUSSION AND ANALYSIS

Introduction

The following management's discussion and analysis ("MD&A") of the financial condition and results of the operations of Cardiol Therapeutics Inc. and its subsidiary (the "Corporation" or "Cardiol") constitutes management of the Corporation's ("Management") review of the factors that affected the Corporation's financial and operating performance for the three and nine months ended September 30, 2026 (the "2026 Fiscal Period"). This discussion should be read in conjunction with the consolidated financial statements for the years ended December 31, 2025, and 2024, and the unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2026 ("Financial Statements"), together with the respective notes thereto. The Financial Statements and the financial information contained in this MD&A are derived from the Financial Statements prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements required by International Financial Reporting Standards and International Accounting Standard as issued by the International Accounting Standards Board (IASB) and Interpretations (collectively "IFRS Accounting Standards"). In the opinion of Management, all adjustments (which consist only of normal recurring adjustments) considered necessary for a fair presentation have been included.

This MD&A is dated November 12, 2026. All dollar amounts in this MD&A are reported in Canadian dollars, unless otherwise stated. Unless otherwise noted or the context indicates otherwise, the terms "we", "us", "our", "Cardiol", the "Company" or the "Corporation" refer to Cardiol Therapeutics Inc. and its subsidiary.

This MD&A is presented current to November 12, 2026, unless otherwise stated. The financial information presented in this MD&A is derived from the Financial Statements. This MD&A contains forward-looking information that involves risks, uncertainties, and assumptions, including statements regarding anticipated developments in future financial periods and our plans and objectives. There can be no assurance that such information will prove to be accurate, and readers are cautioned not to place undue reliance on such forward-looking information. See "Forward-Looking Information" and "Risk Factors".

Forward-Looking Information

This MD&A includes certain "forward looking information" within the meaning of applicable Canadian securities legislation and "forward-looking statements" within the meaning of applicable U.S. securities legislation (collectively, "Forward-Looking Information"). Forward-looking information can be identified by words or phrases such as: "may", "might", "could", "will", "expect", "anticipate", "estimate", "intend", "plan", "indicate", "seek", "believe", "predict", or "likely", or the negative of these terms, or other similar expressions or references to future periods. All information other than historical facts, included in this MD&A that address activities, events or developments that the Corporation expects or anticipates will or may occur in the future, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Corporation's business, operations, plans and other such matters is intended to identify forward-looking information. Statements containing forward-looking information are not historical facts.

The Corporation has based the forward-looking information on its current expectations and projections about future events and financial trends that it believes might affect its financial condition, results of operations, business strategy, and financial needs. The forward-looking information includes, among other things, statements relating to:

- our anticipated cash needs, and the need for additional financing;
- our development of our product candidates for use in testing, research, pre-clinical studies, clinical studies, and commercialization, if approved;
- our ability to develop new routes of administration of our product candidates, including parenteral, for use in testing, research, pre-clinical studies, clinical studies, and commercialization, if approved;
- our ability to develop new formulations of our product candidates for use in testing, research, pre-clinical studies, clinical studies, and commercialization, if approved;
- the successful development and commercialization, if approved, of our current product candidates and the addition of future products and product candidates;
- the ability of our product delivery technologies to deliver our product candidates to inflamed and/or fibrotic tissue;
- our intention to build a pharmaceutical brand and our products focused on addressing inflammation and fibrosis in heart disease, including, but not limited to, acute myocarditis, recurrent pericarditis, and heart failure;

- the expected medical benefits, viability, safety, efficacy, effectiveness, and dosing of our product candidates;
- our patents and intellectual property, including, but not limited to, our (a) ability to procure, defend, and/or enforce our intellectual property relating to our products, product formulations, routes of administration, product candidates, and associated uses, methods, and/or processes, and (b) freedom to operate;
- our competitive position and the regulatory environment in which we operate;
- the molecular targets and mechanism of action of our product candidates;
- our financial position; our business strategy; our growth strategies; our operations; our financial results; our dividend policy; our plans and objectives; and
- expectations of future results, performance, milestones, achievements, prospects, opportunities, or the market in which we operate.

In addition, any statements that refer to expectations, intentions, projections, or other characterizations of future events or circumstances contain forward-looking information. Forward-looking information is based on certain assumptions and analyses made by the Corporation in light of the experience and perception of historical trends, current conditions, and expected future developments and other factors it believes are appropriate and are subject to risks and uncertainties. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with this forward-looking information. Given these risks, uncertainties, and assumptions, prospective investors should not place undue reliance on this forward-looking information. Whether actual results, performance, or achievements will conform to the Corporation's expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions, and other factors, including those listed under "*Risk Factors*", which include:

- the inherent uncertainty of product development including testing, research, pre-clinical studies, and clinical trials;
- our requirement for additional financing;
- our negative cash flow from operations;
- our history of losses;
- dependence on the success of our product candidates which may not generate revenue, if approved;
- reliance on management, loss of members of management or other key personnel, or an inability to attract new management team members;
- our ability to successfully design, initiate, execute, and complete clinical trials, including the high cost, uncertainty, and delay of clinical trials and additional costs associated with any failed clinical trials;
- the uncertainty our investigational products will have a therapeutic benefit in the clinical indications we are pursuing;
- potential equivocal or negative results from clinical trials and their adverse impacts on our future commercialization efforts;
- our ability to receive and maintain regulatory exclusivities in multiple jurisdictions, including Orphan Drug/Medicine Designations/Approvals, for our product candidates;
- delays in achievement of projected development goals;
- management of additional regulatory burdens;
- volatility in the market price for the common shares;
- failure to protect and maintain and the consequential loss of intellectual property rights;
- third-party claims relating to misappropriation by the Corporation of their intellectual property;
- reliance on third parties to conduct and monitor our pre-clinical studies and clinical trials;
- our product candidates being subject to controlled substance laws which may vary from jurisdiction to jurisdiction;
- changes in laws, regulations, and guidelines relating to our business, including tax and accounting requirements;
- our reliance on research regarding the medical benefits, viability, safety, efficacy, and dosing of our product candidates;
- claims for personal injury or death arising from the use of our future products and product candidates;
- uncertainty relating to market acceptance of our product candidates, if approved;
- our lack of experience in commercializing any products, including selling, marketing, or distributing pharmaceutical products;
- securing third-party payor reimbursement for our product candidates, if approved;
- the level of pricing and reimbursement for our product candidates, if approved;
- our dependence on contract manufacturers;
- unsuccessful collaborations with third parties;
- business disruptions affecting third-party suppliers and manufacturers;
- delays in the timing of regulatory authority decision-making, actions, and meetings as a result of workforce re-

alignment, and potentially significant reductions in workforce or other resources, including at the United States Food and Drug Administration ("U.S. FDA") and other U.S. federal agencies;
- lack of control in future production and selling prices of our product candidates, if approved;
- competition in our industry;
- our inability to develop new technologies and products and the obsolescence of existing technologies and products;
- unfavorable publicity or consumer perception towards any products for which we receive marketing authorization;
- product liability claims and product recalls;
- inability to expand our business to other jurisdictions;
- fraudulent activities of employees, contractors, and consultants;
- our reliance on key inputs and their related costs;
- difficulty associated with forecasting demand for products;
- operating risk and insurance coverage;
- our inability to manage growth;
- conflicts of interest among our officers and directors;
- managing damage to our reputation and third-party reputational risks;
- relationships with customers and third-party payors and consequential exposure to applicable anti-kickback, fraud, and abuse and other healthcare laws;
- exposure to information systems security threats;
- no dividends for the foreseeable future;
- future sales of common shares by existing shareholders causing the market price for the common shares to fluctuate;
- the issuance of common shares in the future causing dilution;
- events outside of our control could adversely affect our operations;
- our ability to remediate any material weakness in our internal control over financial reporting;
- global geo-political events, and the responses of governments having a significant effect on the world economy; and
- failure to meet regulatory or ethical expectations on environmental impact, including climate change.

If any of these risks or uncertainties materialize, or if assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those anticipated in the forward-looking information.

Although the Corporation has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events, or results not to be as anticipated, estimated, or intended. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated. The Corporation does not undertake to update forward-looking information if circumstances or management estimates, assumptions, or opinions should change, except as required by applicable law. The reader is cautioned not to unduly rely on forward-looking information. Prospective investors shall be advised that these cautionary remarks expressly qualify all forward-looking statements attributable to the Corporation or persons acting on our behalf.

Overview

On December 20, 2018, the Corporation completed its initial public offering on the Toronto Stock Exchange (the "TSX"), and its common shares commenced trading on the TSX under the symbol "CRDL". On August 10, 2021, the Corporation's common shares also commenced trading on The Nasdaq Capital Market under the symbol "CRDL".

Cardiol Therapeutics Inc. is a late-stage life sciences company advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Corporation’s lead small molecule drug candidate, CardiolRx™ modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAVERIC study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis,

including recurrent pericarditis.

The ARCHER Program also studied CardiolRx™ in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year[1].

Operations Highlights

During the 2026 Fiscal Period

(i) In January 2026, the Corporation announced that it has surpassed 50% of the original target patient enrollment in MAVERIC.

(ii) In January 2026, the Corporation announced the closing of its bought deal financing and full exercise of over-allotment option for gross proceeds of $14.85 million.

(iii) In February 2026, the Corporation announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology.

(iv) In April 2026, the Corporation announced the continued expansion of its pivotal Phase III MAVERIC trial in the United States (“U.S.”), with the planned activation of up to seven additional clinical centers. The Corporation also announced that its original target patient enrollment in MAVERIC reached 75% and full enrollment was anticipated by the end of Q3 2026.

(v) In July 2026, the Corporation announced the publication of its Phase II MAVERIC study results in the Journal of the American Heart Association ("JAHA").

(vi) In September 2026, the Corporation announced that it had received proceeds of over US$7 million from the exercise of outstanding common share purchase warrants.

(vii) In September 2026, the Corporation announced that 110 patients have been enrolled in MAVERIC, achieving the Company’s original recruitment target ahead of its end-of-September guidance. The MAVERIC Steering Committee recommended expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™’s potential to reduce recurrence risk. The recommendation follows a blinded review showing fewer-than-expected recurrences.

Subsequent to September 30, 2026

(i) In November 2026, the Corporation announced it has entered into a sales agreement with Jefferies LLC (the “Sales Agent”) acting as agent in connection with the 2026 at-the-market offering program (the “2026 ATM Program”). Under the terms of the 2026 ATM Program, the Corporation may, from time to time, sell common shares (the “Offered Shares”) having an aggregate value of US$75,000,000 through the Sales Agent on the Nasdaq Capital Market.

The timing and extent of the use of the 2026 ATM Program will be at the discretion of the Corporation and the Corporation has no obligation to sell any shares pursuant to the 2026 ATM Program. Accordingly, total gross proceeds from offerings under the 2026 ATM Program could be less than US$75 million. The 2026 ATM Program will be effective until the earliest of (i) the issuance and sale of all of the Offered Shares issuable pursuant to the 2026 ATM Program, (ii) the date that the 2026 ATM Program is terminated by the Corporation or the Sales Agent pursuant to the terms of the sales agreement, and (iii) the expiry of the Corporation’s Canadian final base shelf prospectus dated September 15, 2026. Subsequent to September 30, 2026, US$4.55 million of gross proceeds was raised under the 2026 ATM Program.

MAVERIC PROGRAM IN RECURRENT PERICARDITIS

Pericarditis refers to inflammation of the pericardium (the membrane or sac that surrounds the heart), frequently

resulting from a viral infection. Recurrent pericarditis is the reappearance of symptoms after a symptom-free period of at least four to six weeks following the initial acute episode of pericarditis. Patients may have multiple recurrences. Symptoms include debilitating chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Causes of pericarditis can include infection, usually viral, systemic disorders such as autoimmune and inflammatory diseases, cancer, and post-cardiac injury syndromes. Pericarditis (and its recurrences) are symptomatic events, the diagnosis of which is based on meeting two of four criteria: chest pain; pericardial friction rub; electrocardiogram changes; and new or worsening pericardial swelling. Elevation of inflammatory markers such as C-reactive protein ("CRP"), and evidence of pericardial inflammation by an imaging technique (computed tomography scan or cardiac magnetic resonance) may help the diagnosis and the monitoring of disease activity. Although generally self-limited and not life threatening, pericarditis is diagnosed in 0.2% of all cardiovascular in-hospital admissions and is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe[2].

Recurrent pericarditis appears in 15% to 30% of patients following the acute index episode and usually within 18 months. Furthermore, up to 50% of patients with a recurrent episode of pericarditis experience more recurrences. Standard first-line medical therapy consists of non-steroidal anti-inflammatory drugs with or without colchicine. Corticosteroids such as prednisone are second-line therapy in patients with continued recurrence and inadequate response to conventional therapy. The only U.S. FDA-approved therapy for recurrent pericarditis, launched in 2021, is a costly subcutaneously injected interleukin-1 blocker with immunosuppressive effects. It is generally used as a third-line intervention in patients with persistent underlying disease, multiple recurrences, and an inadequate response to conventional therapy[2].

On an annual basis, the number of patients in the U.S. having experienced at least one recurrence is estimated at 40,000. Approximately 60% of patients with multiple recurrences (>1) still suffer for longer than two years, and one-third are still impacted at five years. Hospitalization due to recurrent pericarditis is often associated with a 6 – 8-day length of stay and cost per stay is estimated to range between U.S.$20,000 and U.S.$30,000 in the U.S.[2].

Recurrent pericarditis is a rare disease in the U.S., and in February 2024, the U.S. FDA granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis.

The MAVERIC Program is led by an independent Steering Committee ("SC"), consisting of international thought leaders in cardiovascular disease, including:

- **MAVERIC Program Chair: Allan L. Klein, MD, FRCP(C), FACC, FAHA, FASE, FESC** – Director, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart, Vascular and Thoracic Institute, Cleveland Clinic and Professor of Medicine at Lerner College of Medicine of Case Western University;
- **MAVERIC Program Co-Chair: Massimo Imazio, MD, FESC** – Full Professor of Cardiology, Department of Medicine (DMED), University of Udine; Head of Cardiology & Cardiothoracic Department, Santa Maria della Misericordia University Hospital in Udine, Italy;
- **SC Member and MAVERIC Phase II Study Principal Investigator: Allen Luis, MBBS, PhD** – Co-Director of the Pericardial Diseases Clinic, Associate Professor of Medicine, Department of Cardiovascular Medicine, at Mayo Clinic, Rochester, Minnesota;
- **SC Member and MAVERIC Phase III Trial Principal Investigator: Paul Cremer, MD** – Departments of Medicine and Radiology, Northwestern University, and Multimodality Cardiac Imaging and Clinical Trials Unit, Bluhm Cardiovascular Institute;
- **SC Member: Antonio Abbate, MD, PhD** – Ruth C. Heede Professor of Cardiology, School of Medicine, and Department of Medicine, Division of Cardiovascular Medicine – Heart and Vascular Center, University of Virginia;
- **SC Member: Stephen Nicholls, MBBS, PhD** – Program Director, Victorian Heart Hospital, Director, Monash Victorian Heart Institute, and Professor of Cardiology, Monash University, Melbourne;
- **SC Member: Tom Wang, MBChB, MD** – Previously, Cardiologist and Co-director, Pericardial Diseases Center, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute of Cleveland Clinic; Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University;
- **SC Member: Mohamed M Al-Kazaz, MD –** Cardiologist, Northwestern Medicine Bluhm Cardiovascular Institute; Assistant Professor of Medicine (Cardiology), Northwestern University Feinberg School of Medicine; Medical Director, Pericardial Disease Clinic;
- **SC Member: Dor Lotan, MD –** Assistant Professor of Medicine, Director Center for Pericardial Diseases, Columbia

University Irving Medical Center; and

- **SC Member: Jonathan Salik, MD MS-HPED –** Director, Pericardial Disease Program, Harvard Medical School, and Massachusetts General Hospital, Boston, MA.

Recurrent Pericarditis – Phase II MAVERIC Study (MAVERIC-Phase II)

The completed MAVERIC-Phase II open label study enrolled 27 patients at eight prominent clinical centers in the U.S. specializing in pericardial disease care. The primary efficacy endpoint of the study is the change, from baseline to eight weeks, in patient-reported pericarditis pain using an 11-point numeric rating scale ("NRS"). The NRS is a validated clinical tool used across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis. Secondary endpoints include the change in NRS pain score after 26 weeks of treatment, and changes in high sensitivity CRP. Importantly, the study assessed freedom from pericarditis recurrence.

In June 2024, the Corporation reported positive topline 8-week clinical data from its MAVERIC-Phase II study and in November 2024, the Corporation reported comprehensive MAVERIC-Phase II study results concurrent with the American Heart Association Scientific Sessions 2024. The data were included in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture at the American Heart Association Scientific Sessions 2024. Dr. S. Allen Luis, Co-Director of the Pericardial Diseases Clinic and Associate Professor of Medicine in the Department of Cardiovascular Medicine at the Mayo Clinic, presented on behalf of the MAVERIC-Phase II investigators. In July 2026, the Corporation announced the publication of its Phase II MAVERIC study results in the Journal of the American Heart Association ("JAHA").

Baseline characteristics reflected a patient cohort with high disease burden. The average age of participants was 53 years, and 67% were female. The mean disease duration and the average number of pericarditis episodes per year prior to trial entry were 2.7 years and 5.8 events per year, respectively. The number of previous episodes of pericarditis was distributed as follows: 9 patients (33%) with 2 previous episodes; 9 (33%) with 3; 4 (15%) with 4; and 5 (19%) with more than four. Baseline pericarditis pain score averaged 5.8 on a 10-point scale, and the mean CRP level was 2.0 mg/dL. In addition to pericarditis chest pain, other manifestations of pericarditis-confirmed diagnosis were pericardial effusion in 21 patients (78%), pericardial rub in 4 (15%), and ST-segment elevation or PR depression in 5 (19%). Stable doses of baseline medications for recurrent pericarditis, in any combination, included colchicine (85% of patients), non-steroidal anti-inflammatory drugs (78%), and corticosteroids (41%). The 26-week study consisted of an 8-week treatment period (“TP”) followed by an 18-week extension period (“EP”). In the first 10 days of the TP, CardiolRx™ was added to baseline medications for recurrent pericarditis and up titrated to 10 mg/kg twice daily, or the maximum tolerated dose. Throughout the TP, patients continued receiving this concomitant therapy but were weaned off baseline medications during the EP to assess pericarditis recurrence while on CardiolRx™ monotherapy.

Key results:

- Primary endpoint of patient-reported pericardial pain on the 11-point NRS from 0-10 showed a mean reduction of 3.7, from 5.8 at baseline (range of 4 to 10) to 2.1 (range of 0 to 6) at week 8. NRS is a validated instrument used to assess patient-reported pericarditis pain. Zero represents ‘no pain at all’, whereas the upper limit of 10 represents ‘the worst pain ever possible’.
- Median time to resolution or near resolution of pain (defined as a score of <= 2) was rapid and was observed just 5 days following initiation of CardiolRx™ treatment.
- At week 8, 93% (25/27) of patients reported a pain score reduction.
- Reduction in pain was maintained throughout the duration of the trial with a mean reduction of 4.3, from 5.8 at baseline to 1.5 at week 26.
- CRP levels for the entire group of patients were reduced from 2.0 mg/dL at baseline to 0.74 and 0.55 at weeks 8 and 26 respectively, with a median time to CRP normalization of 21 days. CRP is a commonly used clinical marker of inflammation, and in combination with the NRS score, is used by clinicians to assess clinical response and determine a recurrence.
- CRP normalized (<=0.5 mg/dL) at week 8 in 80% (8/10) of the patients with a baseline CRP of >=1 mg/dL, with a substantial mean reduction of 5.4 mg/dL being observed (5.7mg/dL to 0.3 mg/dL).
- Freedom from recurrence was maintained in 71% (17/24) of patients during the EP when CardiolRx™ was continued, and patients were weaned off baseline medications. For those patients experiencing a recurrence the median time to an episode was 7.7 weeks during the EP.
- Number of pericarditis episodes per year was markedly reduced from 5.8 prior to study to 0.9 during the study.
- CardiolRx™ was well tolerated with eighty-nine percent of patients (24/27) progressing to the EP and overall study

drug compliance reported at 95%.

In summary, marked, rapid, and durable reductions in both pericarditis pain and inflammation were observed in the MAVERIC-Phase II study and importantly these reductions were maintained throughout the 6-month study in a recurrent pericarditis population who presented with significant disease burden. In addition, CardiolRx™ substantially reduced the number of pericarditis episodes per year.

On the basis of the MAVERIC-Phase II study findings, Cardiol commenced patient enrollment in a pivotal Phase III clinical trial designed to definitively assess the impact of CardiolRx™ on pericarditis recurrence in a patient population at high risk for recurrence. See “Phase III Trial – Recurrent Pericarditis (MAVERIC)”.

Phase III Trial – Recurrent Pericarditis (MAVERIC)

Cardiol’s Phase III MAVERIC trial is designed to definitively assess the impact of CardiolRx™ on the risk of pericarditis recurrence. The randomized, double-blind, placebo-controlled study, which has a primary efficacy endpoint of time to a new episode of recurrent pericarditis, was originally anticipated to enroll approximately 110 patients at up to 25 clinical sites in the United States.

On September 23, 2026, the Corporation issued a press release announcing that MAVERIC had achieved its original recruitment target of 110 patients and that the Steering Committee had recommended expanding enrollment to approximately 150 patients. The recommendation followed a blinded review showing fewer-than-anticipated pericarditis recurrences across the combined study population. As MAVERIC’s efficacy assessment depends on the number of recurrence events observed, the expanded enrollment is intended to capture sufficient events to preserve the study’s planned statistical power and support a robust evaluation of CardiolRx™’s potential to reduce recurrence risk. Topline results are anticipated in mid-2027, following completion of expanded enrollment and the required patient follow-up.

MAVERIC is recruiting patients at high risk of recurrence following cessation of IL-1 blocker therapy, a setting associated with increased IL-1–driven disease recurrence. Should CardiolRx™ demonstrate a significant reduction in recurrence rates, the study will provide evidence that the drug favorably modulates the pro-inflammatory cytokine profile.

IL-1 is a key pro-inflammatory cytokine in the pathophysiology of recurrent pericarditis. It is generated downstream following activation of the NLRP3 inflammasome and amplifies the autoinflammatory response characteristic of the disease. CardiolRx™ has been shown experimentally to inhibit the assembly and activation of the NLRP3 inflammasome and the subsequent generation of IL-1. Results from the MAVERIC-Phase II study demonstrated that treatment with CardiolRx™ led to marked reductions in pericarditis pain and recurrence episodes. These findings provide the rationale for undertaking the MAVERIC Phase III trial.

The Corporation has budgeted costs to complete this study to be approximately $7 million. If the MAVERIC trial meets its objectives, the details of next steps will be determined in consultation with regulatory agencies and the Corporation's external clinical advisors. Based on a successful end-of-Phase II meeting with the U.S. FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application. The Corporation may involve a pharmaceutical industry partner to fund commercialization of CardiolRx™ for the treatment of recurrent pericarditis.

ARCHER PROGRAM IN ACUTE MYOCARDITIS

Myocarditis is an acute inflammatory condition of the heart muscle (myocardium) characterized by chest pain, impaired cardiac function, atrial and ventricular arrhythmias, and conduction disturbances. Although the symptoms are often mild, myocarditis remains an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people under 35 years of age. Although viral infection is the most common cause of myocarditis, the condition can also result from administration of therapies used to treat several common cancers, including chemo-therapeutic agents and immune checkpoint inhibitors[3].

In a proportion of patients, the inflammation in the heart persists and causes decreased heart function with symptoms and signs of heart failure, and as such pharmacological treatment is based on conventional therapy for heart failure. This includes diuretics, ACE inhibitors, angiotensin receptors blockers, beta blockers, and aldosterone inhibitors. For those with a fulminant presentation, intensive care is often required, with the use of inotropic medications (to increase the force of the heart muscle contraction). Severe cases frequently require ventricular assist devices or extracorporeal oxygenation and may necessitate heart transplantation. There are no U.S. FDA-approved therapies for acute

myocarditis. Patients hospitalized with acute myocarditis experience an average 7-day length of stay and a 4 – 6% risk of in-hospital mortality, with average hospital charge per stay estimated at U.S.$110,000 in the U.S.[3].

Data from multiple sources, including the 'Global Burden of Disease Study', reports that the number of cases of myocarditis per year range from approximately 10 to 22/100,000 persons (estimated U.S. patient population of 33,000 to 73,000), qualifying the condition as a rare disease in the U.S. and in European Union. Cardiol believes that there is a significant opportunity to develop a therapy for acute myocarditis that may be eligible for designation as an orphan drug under the U.S. FDA's Orphan Drug Designation and the European Medicines Agency Orphan Medicine programs[3].

The Corporation's Phase II ARCHER trial (ARCHER) was designed in collaboration with an independent steering committee comprising distinguished thought leaders in heart failure and myocarditis from international centers of excellence. The primary endpoints of the trial, which were evaluated after 12 weeks of double-blind therapy, consist of the following CMR measures: myocardial edema/fibrosis (extra-cellular volume) and left ventricular ("LV") function (global longitudinal strain). Additional CMR measures of interest include change in LV mass.

The ARCHER Steering Committee comprised distinguished thought leaders in heart failure and myocarditis from international centers of excellence who contributed to the design and execution of the ARCHER trial.

- **Chair: Dennis M. McNamara, MD** – Professor of Medicine at the University of Pittsburgh, Director of the Center for Heart Failure Research at the University of Pittsburgh Medical Center;
- **Co-Chair: Leslie T. Cooper, Jr., MD** – General cardiologist and the Elizabeth C. Lane, Ph.D. and M. Nadine Zimmerman, Ph.D. Professor of Internal Medicine, Mayo Clinic, Jacksonville, FL;
- **Arvind Bhimaraj, MD** – Specialist in Heart Failure and Transplantation Cardiology; Houston Heart, HCA Healthcare (Sept 2027);
- **Wai Hong Wilson Tang, MD** – Advanced Heart Failure and Transplant Cardiology specialist at the Cleveland Clinic in Cleveland, Ohio. Dr. Tang is also the Director of the Cleveland Clinic's Center for Clinical Genomics; Research Director, and staff cardiologist in the Section of Heart Failure and Cardiac Transplantation Medicine in the Sydell and Arnold Miller Family Heart & Vascular Institute at the Cleveland Clinic;
- **Peter Liu, MD** – Chief Scientific Officer and Vice President, Research, of the University of Ottawa Heart Institute, and Professor of Medicine and Physiology at the University of Toronto and University of Ottawa;
- **Carsten Tschöpe, MD** – Clinical Professor in Cardiology, Head of the Cardiomyopathy Unit, Department of Cardiology, Angiology and Intensive Care, Campus Virchow, German Heart Center (DHZC) at Charité, Berlin;
- **Matthias Friedrich, MD** – Full Professor within the Departments of Medicine and Diagnostic Radiology at McGill University in Montreal, and Chief, Cardiovascular Imaging at the McGill University Health Centre;
- **Yaron Arbel, MD** – Cardiologist and Director of the CardioVascular Research Center (CVRC) at the Tel Aviv "Sourasky" Medical Center;
- **Edimar Bocchi, MD** – Serves as the Head of Heart Failure Clinics and Heart Failure Team at Heart Institute (Incor) of Hospital das Clinicas of São Paulo University Medical School, Associate Professor of São University Medical School, São Paulo, Brazil; and
- **Mathieu Kerneis, MD, PhD** – Interventional cardiologist at Pitié Salpêtrière Hospital (Sorbonne University), and ACTION Study Group Investigator.

In August 2025, the Corporation announced topline results from the ARCHER trial, which completed with 109 enrolled patients at leading cardiovascular research centers in the United States, France, Brazil, and Israel.

In the two primary endpoints, extracellular volume ("ECV") and global longitudinal strain ("GLS"), CardiolRx™ showed a notable improvement in ECV ($p = 0.0538$) compared to placebo following 12 weeks of double-blind therapy. No significant difference was observed in GLS in a population that had predominantly preserved left ventricular function at baseline. The reduction in ECV was associated with improvements over placebo in multiple pre-specified CMR endpoints, including a significant reduction in LV mass.

The ARCHER trial results provide compelling clinical proof of concept for CardiolRx™ and support advancing the clinical development of CardiolRx™ and CRD-38 in cardiomyopathies, heart failure, and myocarditis. Consistent with findings from Cardiol's MAVERIC-Phase II trial in recurrent pericarditis, CardiolRx™ was shown to be safe and well tolerated. The ARCHER results were presented in an oral session at the Annual Meeting of the European Society of Cardiology (ESC) Working Group on Myocardial & Pericardial Disease (M&PD) in Trieste, Italy, on November 29, 2025, and subsequently published in a February 2026 issue of the journal *ESC Heart Failure*.

The Corporation is reviewing the full ARCHER results with key opinion leaders in myocarditis and heart failure, regulatory agencies, and representatives from the pharmaceutical industry to determine next steps. Following these discussions, the Corporation will provide an update regarding the timeline for completing potential additional clinical development programs based on the ARCHER data, as well as associated costs—all of which will depend on a variety of factors. The Corporation also may involve a pharmaceutical industry partner to support additional clinical development and commercialization of CardiolRx™ and CRD-38 for the treatment of myocarditis, and other inflammatory cardiac conditions including heart failure.

CRD-38 PROGRAM FOR TREATMENT OF HEART DISEASE

Cardiol is developing CRD-38, a novel subcutaneously administered cannabidiol formulation intended for the treatment of heart failure and other inflammatory cardiac conditions. In pre-clinical studies, this novel therapy demonstrated cardioprotective effects, including improvements in cardiac function and reductions in cardiac hypertrophy, fibrosis, and inflammation. The Corporation is currently conducting formulation optimization studies and Investigational New Drug ("IND")-enabling studies necessary to support a future IND application with the U.S. FDA to initiate first-in-human Phase I clinical studies. The Corporation has budgeted approximately $4 million to complete these IND-enabling studies, which are underway and are currently anticipated to be completed by H1 2027.

If Cardiol determines that the IND-enabling studies meet its objectives, next steps related to the clinical development of CRD-38 will be assessed in consultation with external clinical advisors and regulatory agencies. The total cost and timeline to complete this clinical development program cannot be determined at this stage as this will depend on a variety of factors. The Corporation may involve a commercial partner from the pharmaceutical industry to fund the clinical development and commercialization of CRD-38.

Scientific Advisory Board

The Corporation has established a Scientific Advisory Board comprised of distinguished thought leaders in cardiovascular medicine. These individuals will lend their expertise in cardiovascular research and provide invaluable guidance to the Corporation's research and clinical programs. The Scientific Advisory Board members include:

Paul M. Ridker, MD, MPH

Dr. Paul Ridker is Director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital in Boston, where he leads a major translational research program focused mainly on inflammation in atherosclerotic cardiovascular disease. He is the Eugene Braunwald Professor of Medicine at Harvard Medical School and Professor of Epidemiology at the Harvard T.H. Chan School of Public Health.

Dr. Ridker received his medical degree from Harvard School of Medicine and completed an internal medicine residency and a cardiology fellowship at Brigham and Women’s Hospital. Dr. Ridker is board certified in internal medicine. His clinical interests include coronary artery disease and the prevention of atherosclerotic events in high risk populations. Internationally recognized for defining the role of inflammation in atherothrombosis, Dr. Ridker’s primary research has focused on inflammatory mediators of heart disease, biomarkers such as high sensitivity C reactive protein, and the molecular and genetic epidemiology. He has served as Principal Investigator or Study Chair for multiple large, international randomized trials demonstrating that targeting vascular inflammation can reduce major adverse cardiovascular events, thereby directly informing the development of novel anti-inflammatory strategies for the prevention and treatment of coronary disease.

Dr. Ridker is the author of over 900 original reports plus 150 reviews and book chapters, and six textbooks related to cardiovascular medicine. He has a long tenure of serving on the Board of External Experts for the National Heart Lung and Blood Institute (NHLBI), as well as on multiple US FDA review panels and has delivered many invited lectures worldwide.

His contributions to cardiovascular prevention and inflammation biology have been recognized with numerous honors, exemplified by his inclusion in TIME magazine’s list of 100 most influential people of 2004, ranking among the ten most cited cardiovascular researchers worldwide between 2000 and 2010, the American Heart Association Distinguished Scientist Award (2013), the Braunwald Lecture of the American College of Cardiology (2019), the Gotto Prize for Atherosclerosis Research from the International Atherosclerosis Society (2021), and election to the National Academy of Medicine (USA).

Bruce McManus, PhD, MD

Dr. McManus is Professor Emeritus, Department of Pathology and Laboratory Medicine at the University of British Columbia and an internationally recognized leader in inflammatory heart disease with a particular focus on viral myocarditis and heart failure. His academic and leadership roles have spanned CEO of the Centre of Excellence for Prevention of Organ Failure (PROOF Centre), Director of the UBC Centre for Heart Lung Innovation, the inaugural Director of the Providence Heart and Lung Institute at St. Paul's Hospital, Co-Director of the community-wide Institute for Heart and Lung Health, and inaugural Scientific Director of the Institute of Circulatory and Respiratory Health at the Canadian Institutes of Health Research.

Dr. McManus's investigative work relates to mechanisms, consequences, and detection of myocardial injury and aberrant repair in inflammatory diseases of the heart and blood vessels, informing contemporary approaches to the diagnosis and management of acute viral myocarditis and its progression to heart failure. His life's scholarship includes more than 450 peer-reviewed publications, over 60 invited chapters, and several books, and he has trained a generation of clinicians and scientists who are advancing novel therapies for inflammatory cardiomyopathies.

Dr. McManus holds BA and MD degrees from the University of Saskatchewan, an MSc from Pennsylvania State University, and a PhD from the University of Toledo. He completed post-doctoral fellowships in Environmental Physiology at the University of California, Santa Barbara and Cardiovascular & Pulmonary Pathology at the National Heart, Lung, and Blood Institute in Bethesda, as well as residency training in Internal Medicine and Pathology at the Peter Bent Brigham Hospital, Harvard University. Prior to his appointment at the University of British Columbia, Dr. McManus served on the faculty of the University of Nebraska Medical Center for eleven years.

Dr. McManus has been widely honored for his scientific and mentoring contributions, including the prestigious Max Planck Research Award, the Distinguished Achievement Award by the Society for Cardiovascular Pathology, the Howard Morgan Award from the International Academy of Cardiovascular Sciences, and the Lifetime Achievement Award from Canadian Blood Services. He is a Fellow of the Royal Society of Canada and has been appointed to both the Order of Canada and the Order of British Columbia.

Joseph A. Hill, MD, PhD

Dr. Hill is Professor of Internal Medicine and Molecular Biology at UT Southwestern Medical Center in Dallas, TX, and Director of the Harry S. Moss Heart Center. He served as Chief of Cardiology at UT Southwestern for 21 years prior to stepping down in 2023.

Dr. Hill holds the James T. Willerson, MD, Distinguished Chair in Cardiovascular Diseases, and the Frank M. Ryburn Jr. Chair in Heart Research. His research focuses on molecular mechanisms of structural, functional, metabolic, and electrophysiological remodeling in cardiac hypertrophy and heart failure, with direct relevance to developing novel therapies for inflammatory and fibrotic heart disease.

After graduating from Duke University with MD and PhD degrees in 1987, Dr. Hill completed a five-year postdoctoral fellowship in molecular neurobiology at the Institut Pasteur in Paris, studying central and peripheral nicotinic receptors. Subsequently, he completed an internal medicine internship and residency, as well as a clinical cardiology fellowship, at the Brigham and Women's Hospital, Harvard Medical School.

After serving on the faculty at the University of Iowa for five years, Dr. Hill joined UT Southwestern in 2002 as Chief of Cardiology, where he has built a translational research program aimed at elucidating pathways that drive adverse cardiac remodeling and heart failure progression. His work has helped identify molecular targets with potential to modulate inflammation, fibrosis, and cardiomyocyte survival, supporting the development of next-generation cardioprotective therapies.

In addition to publishing nearly 280 scholarly articles, Dr. Hill has co-edited a major textbook and has contributed chapters to 14 books. He has served on many NIH panels and committees and delivered numerous invited lectures worldwide. His contributions have been recognized with multiple honors, including the 2018 Research Achievement Award from the International Society for Heart Research, the 2019 Louis and Artur Lucian Award from McGill University, the 2023 Medal of Merit from the International Academy of Cardiovascular Sciences, the 2025 Gill Heart and Vascular Institute Award for Outstanding Contributions to Cardiovascular Research, and the 2025 Bohuslav Ostadal Award for Excellence in Cardiovascular Sciences from the International Academy of Cardiovascular Sciences.

Dr. Hill has served on the editorial boards and as a reviewer for leading journals, including the Journal of the American

Medical Association, Circulation, Circulation Research, American Journal of Cardiology, and Proceedings of the National Academy of Sciences of the USA. In addition, Dr. Hill served a 10-year tenure as the Editor-in-Chief of the esteemed American Heart Association journal Circulation.

Outlook

Within the next 12 – 18 months, the Corporation expects to achieve the following:

- Complete the pivotal Phase III MAVERIC trial evaluating the impact of CardiolRx™ on pericarditis recurrence and report results;
- Advance business development discussions with prospective strategic partners; and
- Subject to the outcomes of the IND-enabling studies, initiate the clinical development of CRD-38.

The Corporation expects that the September 30, 2026, cash and cash equivalents of $29.2 million will be sufficient to fund operations and capital requirements associated with achieving these corporation milestones, into Q1, 2028.

The cash and cash equivalents balance as of November 12, 2026, including the net proceeds from the 2026 ATM Program, is $33.2 million.

Use of Offering Proceeds

On October 10, 2024, the Corporation completed an offering (the "October 2024 Offering") of 9,703,125 Common Shares for net proceeds of US$14,112,500 pursuant to a prospectus supplement dated October 8, 2024 (the "October 2024 Prospectus"). The following table compares the disclosure the Corporation previously made in the October 2024 Prospectus about how the Corporation intended to use the proceeds from the October 2024 Offering at that time compared to the Corporation's actual use of proceeds from the October 2024 Offering as at September 30, 2026 and accounts for any variances between the two sets of disclosure. Figures in the below are translated to CAD from USD at a rate of 1.42.

	Anticipated Use of Proceeds ($)	Actual Use of Proceeds as at September 30, 2026 ($)
Support the clinical development of CardiolRx™ for the treatment of recurrent pericarditis	20,020,840	11,200,000
General and administrative expenses, working capital and other research and development expenses		8,020,840

A comparison between the projected Use of Available Funds, as defined and disclosed in the LIFE Offering Document dated January 16, 2026, and spending from January 1, 2026 to September 30, 2026 is as follows:

	Amount ($)	Spent ($)
Complete Phase III MAVERIC trial in recurrent pericarditis with CardiolRx™	10,000,000	5,700,000
Advance the development of CRD-38 into a clinical program	3,400,000	1,600,000
Complete Phase 1 study with CRD-38	3,000,000	nil
General and administrative expenses, working capital and other research and development expenses	17,459,000	12,600,000

Summary of Quarterly Results

The Corporation's quarterly information in the table below is prepared in accordance with IFRS Accounting Standards.

Three Months Ended	Total Revenue ($)	Profit or (Loss) Total ($)	Profit or (Loss) Per Share[9] ($)	Total Assets ($)
September 30, 2026[1]	nil	(13,324,604)	(0.11)	32,885,787
June 30, 2026[2]	nil	(6,081,827)	(0.05)	29,357,847
March 31, 2026[3]	nil	(10,818,589)	(0.10)	31,406,607
December 31, 2025[4]	nil	(7,212,569)	(0.07)	23,619,933
September 30, 2025[5]	nil	(9,964,281)	(0.12)	12,947,801
June 30, 2025[6]	nil	(8,354,371)	(0.10)	19,937,699
March 31, 2025[7]	nil	(8,287,653)	(0.10)	25,454,895
December 31, 2024[8]	nil	(8,178,310)	(0.10)	31,863,751

Notes:

1. Net loss of $13,324,604 included general and administration of $5,930,672, research and development of $3,871,327, and change in derivative liability of $3,854,360. These are partially offset by gain on foreign exchange of $131,439, and interest income of $200,316.

2. Net loss of $6,081,827 included general and administration of $4,741,864, research and development of $3,196,057. These are partially offset by change in derivative liability of $1,153,088, gain on foreign exchange of $300,668, interest income of $201,332, and other income of $201,006.

3. Net loss of $10,818,589 included general and administration of $4,757,383 and research and development of $4,949,411 and change in derivative liability of $1,529,519. These are partially offset by gain on foreign exchange of $217,000 and interest income of $200,724.

4. Net loss of $7,212,569 included general and administration of $5,288,185 and research and development of $2,742,790 and loss on foreign exchange of $308,546. These are partially offset by interest income of $175,209 and change in derivative liability of $951,743.

5. Net loss of $9,964,281 included general and administration of $5,393,522 and research and development of $4,786,578. These are partially offset by interest income of $122,256 and gain on foreign exchange of $93,563.

6. Net loss of $8,354,371 included general and administration of $4,944,477, research and development of $2,731,681, and loss on foreign exchange of $858,880. These are partially offset by interest income of $180,667.

7. Net loss of $8,287,653 included general and administration of $4,671,651, research and development of $3,757,412, and loss on foreign exchange of $106,859. These are partially offset by interest income of $248,269.

8. Net loss of $8,178,310 included general and administration of $5,760,555, and research and development of $4,228,869. These are partially offset by interest income of $306,775, and gain on foreign exchange of $1,500,692.

9. Basic and fully diluted.

Discussion of Operations

Timing and Expenditures for Programs as at September 30, 2026

Program	Target Date as of June 30, 2026	Revised Target Date as of September 30, 2026	Cumulative Expenses Incurred to September 30, 2026 ($)[4]	Estimated Costs as of June 30, 2026 ($)	Estimated Remaining Costs as of September 30, 2026 ($)	
MAVERIC Program - Phase III trial	Q3 2026	Q4 2026	11,200,000	14,500,000	6,800,000	Note 1
CRD-38 Program - IND-enabling studies	H1 2027	H1 2027	1,600,000	5,400,000	3,800,000	Note 2
ARCHER Program - Next steps being assessed	N/A	N/A	N/A	N/A	N/A	Note 3

Notes:

(1) The Corporation has continued the expansion of its pivotal Phase III MAVERIC trial in the United States. In September 2026, the Corporation announced that 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target. The MAVERIC Steering Committee recommended expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk. Target recruitment is anticipated by the end of Q4 2026. Phase III MAVERIC expenses were $1,664,960 and $5,652,552, respectively, for the three and nine months ended September 30, 2026, as additional trial sites were activated and recruitment accelerated versus the three and nine months ended September 30, 2025, expenses of $2,790,466 and $4,668,875, respectively. If the Phase III MAVERIC trial meets its objectives, the details of next steps will be determined in consultation with regulatory agencies and the Corporation's external clinical advisors. Based on a successful end-of-Phase II meeting with the U.S. FDA and subject to Phase III MAVERIC outcomes, Cardiol believes the results from Phase III MAVERIC will support a New Drug Application. The Corporation may involve a pharmaceutical industry partner to fund commercialization of CardiolRx™ for the treatment of recurrent pericarditis.

(2) The Corporation is currently conducting additional formulation optimization studies as well as Investigational New Drug ("IND")-enabling studies necessary to support a future IND application with the U.S. FDA to initiate first-in-human Phase I clinical studies. CRD38 expenses were $221,859 and $1,626,543, respectively, for the three and nine months ended September 30, 2026, as IND-enabling studies were initiated and formulation optimization studies continued, versus the three and nine months ended September 30, 2025, expenses of $110,149 and $510,613, respectively. If Cardiol determines that the IND-enabling studies meet its objectives, next steps related to the clinical development of CRD-38 will be assessed in consultation with external clinical advisors and regulatory agencies. The total cost and timeline to complete the next steps of the clinical development program cannot be determined at this stage as this will depend on a variety of factors. The Corporation may involve a commercial partner from the pharmaceutical industry to fund the clinical development and commercialization of CRD-38.

(3) ARCHER expenses were $81,323 and $212,789, respectively, for the three and nine months ended September 30, 2026, versus the three and nine months ended September 30, 2025, expenses of $551,183 and $2,076,507, respectively, as the study was completed and reported results in 2025. The Corporation is reviewing the full Phase II ARCHER results with key opinion leaders in myocarditis and heart failure, regulatory agencies, and representatives from the pharmaceutical industry to determine next steps. Following these discussions, the Corporation will provide an update regarding the timeline for completing potential additional clinical development programs based on the ARCHER data, as well as associated costs—all of which will depend on a variety of factors. The Corporation may involve a pharmaceutical industry partner to support additional clinical development and commercialization of CardiolRx™ and CRD-38 for the treatment of myocarditis, and other inflammatory cardiac conditions including heart failure.

(4) Expenses incurred represent cumulative expenditures on the current stage of each program. Program expenditures comprise external contract research and regulatory costs and exclude salaries and benefits and share-based compensation, which are not allocated by program. For MAVERIC, this reflects expenditures on the Phase III study. For CRD-38, this reflects expenditures on the current formulation optimization and IND-enabling studies. As next steps for the ARCHER Program remain under review, there is no current stage in respect of which expenditures are presented.

Variances in General and Administrative Expenses for Three and Nine Months Ended September 30, 2026

	Three months ended September 30, 2026 ($)	Three months ended September 30, 2025 ($)	Nine months ended September 30, 2026 ($)	Nine months ended September 30, 2025 ($)
Administration	**$ 1,875,244**	$ 1,157,329	**$ 4,559,383**	$ 3,778,882
Depreciation of equipment	**12,786**	25,551	**51,041**	76,007
Corporate communications and investor relations	**597,048**	499,161	**1,921,478**	1,716,304
Salaries and benefits	**488,619**	753,126	**3,417,106**	3,202,301
Regulatory	**95,810**	64,371	**308,574**	275,700
Share-based compensation - admin	**2,861,165**	2,893,984	**5,172,337**	5,960,456
Total general and administrative expenses	**$ 5,930,672**	**$ 5,393,522**	**$ 15,429,919**	**$ 15,009,650**
Total general and administrative expenses, excluding non-cash items (i)	**$ 2,757,081**	**$ 2,055,800**	**$ 8,952,737**	**$ 8,543,290**

Note

(i) Total general and administrative expenses, excluding non-cash depreciation, accretion on lease liability, and share-based compensation.

Nine months ended September 30, 2026, compared to the nine months ended September 30, 2025

For the nine months ended September 30, 2026, the Corporation's net loss was $30,225,020, compared to a net loss of $26,606,305 for the nine months ended September 30, 2025. The increase in net loss of $3,618,715 is a result of the following:

- General and administration expenses increased to $15,429,919 for the nine months ended September 30, 2026, compared to $15,009,650 for the nine months ended September 30, 2025. The increase was primarily due to an increase in administration, corporate communications and investor relations, and salaries and benefits, partially offset by a decrease in non-cash share-based compensation. Administration expenses increased to support the overall growth in operations of the Corporation, mainly related to accounting and other professional fees. The increase in salaries and benefits reflects annual compensation adjustments in line with changes in the cost of living. Corporate communications, marketing, and investor relations increased as the Corporation accelerated its investor outreach activities commensurate with improving capital markets. Share-based compensation fluctuates with the number, grant date and vesting terms of awards issued, and the decrease reflects the vesting profile of awards granted in the current and prior periods. No other component of general and administration expenses varied by a material amount during the period.

- Research and development increased to $12,016,795 for the nine months ended September 30, 2026, compared to $11,275,671 for the nine months ended September 30, 2025. During the nine months ended September 30, 2026, the Corporation incurred research and development costs related to basic science, pre-clinical studies, and clinical studies, specifically relating to the ARCHER, MAVERIC, and CRD-38 programs, in the amount of $212,789, $5,652,552, and $1,626,543, respectively. This compares to $2,076,507, $4,668,875, and $510,613, respectively, relating to the ARCHER, MAVERIC, and CRD-38 programs for the nine months ended September 30, 2025. See "Timing and Expenditures for Programs as at September 30, 2026".

- During the nine months ended September 30, 2026, there was a loss on the change in derivative liability of $4,230,791. There was no gain or loss on change in derivative liability for the nine months ended September 30, 2025.

- A gain on foreign exchange is included in the net loss for the nine months ended September 30, 2026, of $649,107, compared to a loss on foreign exchange during the nine months ended September 30, 2025, of $872,176. This is mainly the result of the revaluation of funds held in USD.

- The net loss is partially offset by other income during the nine months ended September 30, 2026, of $201,006, as a result of refundable investment tax credits received under the Scientific Research & Experimental Development program. There was no other income during the nine months ended September 30, 2025.

Three months ended September 30, 2026, compared to the three months ended September 30, 2025

For the three months ended September 30, 2026, the Corporation's net loss was $13,324,604, compared to a net loss of $9,964,281 for the three months ended September 30, 2025. The increase in net loss of $3,360,323 is a result of the following:

- General and administration expense increased to $5,930,672 for the three months ended September 30, 2026, compared to $5,393,522 for the three months ended September 30, 2025. The increase was primarily due to an increase in administration, and corporate communications and investor relations, partially offset by a decrease in salaries and benefits. Administration expenses increased to support the overall growth in operations of the Corporation, mainly related accounting and other professional fees. Corporate communications, marketing, and investor relations increased as the Corporation accelerated its investor outreach activities commensurate with improving capital markets. No other component of general and administration expenses varied by a material amount during the period.

- Research and development decreased to $3,871,327 for the three months ended September 30, 2026, compared to $4,786,578 for the three months ended September 30, 2025. During the three months ended September 30, 2026, the Corporation incurred research and development costs related to basic science, pre-clinical studies, and clinical studies, specifically relating to the ARCHER, MAVERIC, and CRD-38 programs, in the amount of $81,323, $1,664,960, and $221,859 respectively. This compares to $551,183, $2,790,466, and $110,149, respectively, relating to ARCHER, MAVERIC, and CRD-38 programs for the three months ended September 30, 2025. See "Timing and Expenditures for Programs as at September 30, 2026".

- During the three months ended September 30, 2026, there was a loss on the change in derivative liability of $3,854,360. There was no gain or loss on the change in derivative liability for the three months ended September 30, 2025.

- The net loss for the three months ended September 30, 2026 was partially offset by a gain on foreign exchange of $131,439, compared to a gain on foreign exchange during the three months ended September 30, 2025, of $93,563. This is mainly the result of the revaluation of funds held in USD.

Capital Management

The Corporation manages its capital to ensure sufficient financial flexibility to achieve the ongoing business objectives including research activities, funding of future growth opportunities, and pursuit of acquisitions.

The Corporation monitors its capital structure and makes adjustments according to market conditions in an effort to meet its objectives given the current outlook of the business and industry in general. The Corporation may manage its capital structure by issuing new shares, repurchasing outstanding shares, adjusting capital spending, or disposing of assets. The capital structure is reviewed by Management and the Board of Directors on an ongoing basis.

The Corporation considers its capital to be total equity, comprising share capital, contributed surplus, and warrants, less accumulated deficit, which at September 30, 2026, totaled $27,603,254 (December 31, 2025 – $17,877,718).

The Corporation manages capital through its financial and operational forecasting processes. The Corporation reviews its working capital and forecasts its future cash flows based on operating expenditures, and other investing and financing activities. The forecast is updated based on activities related to its research programs and reviewed with the Board of Directors of the Corporation.

The Corporation is not currently subject to any capital requirements imposed by a lending institution or regulatory body.

The Corporation expects that its capital resources will be sufficient to discharge its liabilities as of the current statement of financial position date.

Off-Balance Sheet Arrangements

As of the date of this MD&A, the Corporation does not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the results of operations or financial condition of the Corporation, including, and without limitation, such considerations as liquidity and capital resources.

Liquidity and Capital Resources

At September 30, 2026, Cardiol had $29,229,802 in cash and cash equivalents (December 31, 2025 – $21,416,684).

At September 30, 2026, accounts payable and accrued liabilities were $5,036,450 (December 31, 2025 – $3,478,825). The Corporation's cash and cash equivalents balances as at September 30, 2026, and December 31, 2025, are sufficient to pay these liabilities.

The Corporation currently has no operating revenues and therefore must utilize its funds from financing transactions to maintain its capacity to meet ongoing operating activities. Future financing may come from product sales, licensing arrangements, research and commercial development partnerships, government grants, and/or corporate finance arrangements.

We expect to continue to incur substantial losses as we continue our research and development efforts. We continue to manage our research and development plan to ensure optimal use of our existing resources as we expect to fund our operations and capital requirements, associated with achieving our corporate milestones, with existing working capital (See "Outlook"). We expect to continue to incur additional costs associated with operating as a public company. Factors that may affect our anticipated cash usage, but are not limited to, expansion of our clinical trial programs, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of research and development activity with our clinical trial research collaborations, and other factors described in the "Risk Factors" section.

As of September 30, 2026, December 31, 2025, and to the date of this MD&A, the cash resources of Cardiol are held with one Canadian chartered bank. The Corporation has no variable interest rate debt, and its credit and interest rate risk are minimal. Accounts payable and accrued liabilities are short-term and non-interest bearing.

<u>For the 2026 Fiscal Period</u>

Cash and cash equivalents used in operating activities were $16,474,840 for the nine months ended September 30, 2026. Operating activities were affected by a net loss of $30,225,020, partially offset by net change in non-cash working capital balances of $2,520,495, and other non-cash adjustments of $11,229,685. Non-cash adjustments mainly consisted of $7,665,977 for share-based compensation, and $4,230,791 for change in derivative liability.

Cash and cash equivalents used in investing activities were $75,221 for the nine months ended September 30, 2026, as a result of the purchase of property and equipment.

Cash and cash equivalents provided by financing activities were $23,631,772 for the nine months ended September 30, 2026, as a result of the net proceeds from financing, exercise of warrants, and exercise of stock options, partially offset by payment of lease liability.

<u>Use of Working Capital</u>

As of September 30, 2026, Cardiol's cash and cash equivalents were $29,229,802 and working capital was $27,515,357 ($27,664,166 excluding the non-cash derivative liability). Based on current projections, Cardiol believes that this amount is sufficient to fund operations and capital requirements, associated with achieving corporate milestones into Q1 2028, as described in the "Outlook" section above.

The Corporation has material commitments and obligations for cash resources set out below. The Corporation has no commitments for capital expenditures.

Contractual Obligations	Total ($)	Up to 1 year ($)	1 – 3 years ($)	4 – 5 years ($)	After 5 years ($)
Amounts payable and other liabilities	5,036,450	5,036,450	Nil	Nil	Nil
Office lease[(1)]	223,378	107,222	116,156	Nil	Nil
Consulting agreements	344,295	344,295	Nil	Nil	Nil
Contract research	1,621,256	1,313,575	302,133	5,548	Nil
Total	**7,225,379**	**6,801,542**	**418,289**	**5,548**	**Nil**

Note:
(1) The Corporation has leased premises from third parties.

Related Party Transactions

a) The Corporation entered into the following transactions with related parties:

i. Included in research and development expense is $30,000 and $55,000 for the three and nine months ended September 30, 2026, paid to a company related to a Director. As at September 30, 2026, $11,300 was owed to this company and this amount was included in accounts payable and accrued liabilities. Cardiol entered into an agreement with this company to provide advisory services in connection with the Company's ongoing research and development activities.

ii. General and administration expense includes $44,888 paid to a company related to an Officer and Director for the three and nine months ended September 30, 2026 (three and nine months ended September 30, 2025 – $nil), and $52,014 in share-based compensation expense for the three and nine months ended September 30, 2026 (three and nine months ended September 30, 2025 – $nil). As at September 30, 2026, $nil was owed to this company (December 31, 2025 – $nil), and $8,203 (December 31, 2025 – $nil) was paid to this company and was included in prepaid expenses. Cardiol entered into an agreement with this company to provide content production and creative development services.

b) Key Management personnel are those persons having authority and responsibility for planning, directing, and controlling the activities of the Corporation directly or indirectly, including any Directors (executive and non-executive) of the Corporation. Remuneration of directors and key management personnel was as follows:

	Three months ended September 30, 2026 ($)	Three months ended September 30, 2025 ($)	Nine months ended September 30, 2026 ($)	Nine months ended September 30, 2025 ($)
Salaries and benefits	604,385	570,978	2,499,600	2,446,705
Share-based payments	298,311	248,951	1,107,908	1,187,740
	902,696	**819,929**	**3,607,508**	**3,634,445**

As at September 30, 2026, $76,617 (December 31, 2025 - $nil) was owed to directors and key management personnel.

Critical Accounting Judgments, Estimates, and Assumptions

The preparation of the Financial Statements requires Management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities at the date of the Financial Statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. The Financial Statements include estimates that, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the Financial Statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions, and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates

Significant assumptions about the future that Management has made that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

- the valuation of performance share units;
- the valuation of the derivative liability;
- the estimate of the percentage of completion of certain research and development agreements; and
- the valuation of income tax accounts.

Critical accounting judgments

- Management applied judgment in determining the functional currency of the Corporation as Canadian dollars;
- Management applied judgment in determining whether performance conditions on share-based awards were market or non-market, and whether the fair value of the goods or services provided by certain non-employees could be reliably measured; and
- Management applied judgment in determining the Corporation's ability to continue as a going concern. The Corporation has incurred significant losses since its inception. Management determined that a material going concern uncertainty does not exist due to the sufficient working capital to support their planned expenditure levels. Future financing may come from product sales, licensing arrangements, research and commercial development partnerships, government grants, and/or corporate finance arrangements.

Future Accounting Policies

(i) IFRS 18 - Presentation and disclosure in financial statements

In April 2024, the IASB issued IFRS 18, focusing on presentation and disclosure in financial statements. Key changes would impact the structure of the consolidated statement of loss and comprehensive loss and amendments to disclosure requirements for certain profit or loss performance measures. IFRS 18 will replace IAS 1, effective reporting period beginning on January 1, 2027. This will also impact comparative information at the point of adoption.

An assessment of the applicability of the new standard will be performed on the consolidated financial statements to which the pronouncement applies.

Share Capital

Other than as described below, as of the date of this MD&A, there are no equity or voting securities of the Corporation outstanding, and no securities convertible into, or exercisable or exchangeable for, voting or equity securities of the Corporation.

As of the date of this MD&A, the outstanding capital of the Corporation includes 127,688,399 issued and outstanding common shares; 400,000 common shares issuable to Dalton Chemical Laboratories, Inc. operating as Dalton ("Dalton"), if Dalton meets certain performance objectives, and stock options, warrants, performance share units, and restricted share units as shown below:

Warrants

Expiry date	Exercise price ($)	Warrants outstanding
January 23, 2028	1.75	5,711,539
Total		**5,711,539**

Stock Options

Expiry date	Exercise price ($)	Options outstanding	Options exercisable
December 8, 2026	3.59	325,000	325,000
January 11, 2027	2.18	220,000	220,000
March 1, 2027	2.56	200,000	200,000
March 9, 2027	1.13(1)	200,000	200,000
May 12, 2027	1.46	70,000	70,000
September 13, 2027	1.61	200,000	200,000
July 21, 2028	1.67	50,000	50,000
July 7, 2029	2.07	30,000	20,000
August 19, 2029	1.50	30,000	20,000
May 25, 2030	1.09(1)	120,000	120,000
May 25, 2030	2.12	100,000	100,000
May 29, 2030	1.16(1)	60,000	20,000
December 2, 2030	1.40	2,600,000	-
December 2, 2030	1.00(1)	490,000	-
Total		**4,695,000**	**1,545,000**

(1) Exercise price denoted in USD.

Performance Share Units

The Corporation has 48,475 outstanding performance share units ("PSUs") subject to vesting conditions specific to each grant. Of the outstanding PSUs, none have fully vested as of the date of this MD&A.

Restricted Share Units

The Corporation has 3,641,567 outstanding restricted share units ("RSUs") subject to vesting conditions specific to each grant. Of the outstanding RSUs, 2,539,810 have fully vested as of the date of this MD&A.

Financial Instruments

Recognition

The Corporation recognizes a financial asset or financial liability on the statement of financial position when it becomes party to the contractual provisions of the financial instrument. Financial assets are initially measured at fair value and are derecognized either when the Corporation has transferred substantially all the risks and rewards of ownership of the financial asset, or when cash flows expire. Financial liabilities are initially measured at fair value and are derecognized when the obligation specified in the contract is discharged, cancelled, or expired.

A write-off of a financial asset (or a portion thereof) constitutes a derecognition event. A write-off occurs when the Corporation has no reasonable expectations of recovering the contractual cash flows on a financial asset.

Classification and Measurement

The Corporation determines the classification of its financial instruments at initial recognition. Financial assets and financial liabilities are classified according to the following measurement categories:

- those to be measured subsequently at fair value, either through profit or loss (“FVTPL”) or through other comprehensive income (“FVTOCI”); and,
- those to be measured subsequently at amortized cost.

The classification and measurement of financial assets after initial recognition at fair value depends on the business model for managing the financial asset and the contractual terms of the cash flows. Financial assets that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are

solely payments of principal and interest on the principal outstanding, are generally measured at amortized cost at each subsequent reporting period. All other financial assets are measured at their fair values at each subsequent reporting period, with any changes recorded through profit or loss or through other comprehensive income (which designation is made as an irrevocable election at the time of recognition).

After initial recognition at fair value, financial liabilities are classified and measured at either:

- amortized cost;
- FVTPL, if the Corporation has made an irrevocable election at the time of recognition, or when required (for items such as instruments held for trading or derivatives); or,
- FVTOCI, when the change in fair value is attributable to changes in the Corporation's credit risk.

The Corporation reclassifies financial assets when and only when its business model for managing those assets changes. Financial liabilities are not reclassified.

Transaction costs that are directly attributable to the acquisition or issuance of a financial asset or financial liability classified as subsequently measured at amortized cost are included in the fair value of the instrument on initial recognition. Transaction costs for financial assets and financial liabilities classified at fair value through profit or loss are expensed in profit or loss.

The Corporation's financial assets consist of cash and cash equivalents and accounts receivable, which are classified and measured at amortized cost. The Corporation's financial liabilities consist of accounts payable and accrued liabilities, and lease liability, which are classified and measured at amortized cost, and derivative liabilities which are classified and measured at FVTPL.

Impairment

The Corporation assesses all information available, including on a forward-looking basis the expected credit losses associated with any financial assets carried at amortized cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. To assess whether there is a significant increase in credit risk, the Corporation compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition based on all information available, and reasonable and supportive forward-looking information.

Fair Value

The Corporation provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of the fair value hierarchy are as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2: inputs other than quotes prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Corporation's derivative liabilities were measured at fair value Level 3. The fair value of all other financial instruments approximates their carrying amounts due to the relatively short period to maturity.

Financial Instrument Risks

The Corporation's activities expose it to a variety of financial risks: credit risk, liquidity risk, and market risk (including interest rate and foreign currency risk). These financial risks are in addition to the risks set out under "Risk Factors".

Risk management is carried out by the Corporation's Management team under policies approved by the Board of Directors. The Board of Directors also provides regular guidance for overall risk management.

There were no changes to credit risk, liquidity risk, or market risk for the 2026 Fiscal Period.

Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Corporation's financial instruments that are exposed to concentrations of credit risk relate primarily to cash and cash equivalents and accounts receivable.

The Corporation mitigates its risk by maintaining its funds with large reputable financial institutions, from which Management believes the risk of loss to be minimal. Interest receivable relates to guaranteed investment certificates and cash balances held with large reputable financial institutions as well as receivables. The Corporation's Management considers that all the above financial assets are of good credit quality.

Liquidity risk

Liquidity risk is the risk that the Corporation encounters difficulty in meeting its obligations associated with financial liabilities. Liquidity risk includes the risk that, as a result of operational liquidity requirements, the Corporation will not have sufficient funds to settle a transaction on the due date; will be forced to sell financial assets at a value which is less than what they are worth; or may be unable to settle or recover a financial asset. Liquidity risk arises from accounts payable and accrued liabilities and commitments. The Corporation limits its exposure to this risk by closely monitoring its cash flow.

Market risk

Market risk is the risk of loss that may arise from changes in market factors, such as interest rates and foreign exchange rates.

(a) Interest rate risk

The Corporation currently does not have any short-term or long-term debt that is variable interest bearing and, as such, the Corporation's current exposure to interest rate risk is minimal.

(b) Foreign currency risk

Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in the foreign exchange rates. The Corporation enters into foreign currency purchase transactions and has assets that are denominated in foreign currencies and thus is exposed to the financial risk of earnings fluctuations arising from changes in foreign exchange rates and the degree of volatility of these rates. The Corporation does not currently use derivative instruments to reduce its exposure to foreign currency risk.

The Corporation holds balances in U.S. dollars which could give rise to exposure to foreign exchange risk. Sensitivity to a plus or minus 10% change in the foreign exchange rate of the U.S. dollar against the Canadian dollar would affect the reported loss and comprehensive loss by approximately $1,743,000 (December 31, 2025 – $1,445,000).

Commitments and Contingency

(i) The Corporation has leased premises from third parties. The minimum committed lease payments as at September 30, 2026, which include the lease liability payments, are as follows:

Fiscal year		
2026	$	26,805
2027		107,222
2028		89,351
Total	**$**	**223,378**

(ii) The Corporation has signed various agreements with consultants to provide services. Under the agreements, the Corporation has the following remaining commitments:

Fiscal year		
2026	$	308,619
2027		35,676
Total	**$**	**344,295**

(iii) Pursuant to the terms of agreements with various other contract research organizations, the Corporation is committed for the following contract research services:

Fiscal year		
2026	$	594,618
2027		958,609
2028		45,833
2029		22,196
Total	**$**	**1,621,256**

Breakdown of Expensed Research and Development

	Three months ended September 30, 2026 ($)	**Three months ended September 30, 2025 ($)**	**Nine months ended September 30, 2026 ($)**	**Nine months ended September 30, 2025 ($)**
Contract research	3,016,476	3,504,444	8,665,058	7,638,680
Wages	356,680	371,936	1,445,566	1,572,082
Supplies	-	894	-	7,191
Regulatory	207,661	216,381	653,052	744,111
Share-based compensation	290,510	692,923	1,253,119	1,313,607
	3,871,327	**4,786,578**	**12,016,795**	**11,275,671**

Internal Controls Over Financial Reporting

In accordance with National Instrument 52-109 – Certification of Disclosure in Issuers' Annual and Interim Filings, Management is responsible for establishing and maintaining adequate Disclosure Controls and Procedures ("DCP") and Internal Control Over Financial Reporting ("ICFR"). Management has designed DCP and ICFR based on the 2013 Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"), with the objective of providing reasonable assurance that the Corporation's financial reports and information, including the Corporation's Financial Statements and MD&A were prepared in accordance with IFRS Accounting Standards. The CEO and CFO have concluded that the DCP and ICFR were adequately designed and operating effectively to provide such assurance as at September 30, 2026.

Limitations of Controls and Procedures

The Corporation's Management, including the CEO and CFO, believes that any DCP or ICFR, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, they cannot provide absolute assurance that all control issues and instances of fraud, if any, within the Corporation have been prevented or detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by unauthorized override of the control. The design of any control system is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Accordingly, because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

There have been no changes in internal controls over financial reporting for the quarter ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, the Corporation’s ICFR.

Risk Factors

An investment in the securities of the Corporation is highly speculative and involves numerous and significant risks. Such investment should be undertaken only by investors whose financial resources are sufficient to enable them to assume these risks. Prospective investors should carefully consider the risk factors that have affected, and which in the future are reasonably expected to affect, the Corporation and its financial position. Please refer to the section entitled "Risk Factors" in the Corporation's MD&A for the financial year ended December 31, 2025 (available on SEDAR+ at sedarplus.ca and EDGAR at www.sec.gov).

References

1. Bragazzi NL, Zhong W, Shu J, *et al*. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. *Eur J Prev Cardiol. 2021*;28(15):1682-1690. doi:10.1093/eurjpc/zwaa147

Tsao CW et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023 Jan 25.

2. Adler Y, Charron P. The 2015 ESC Guidelines on the diagnosis and management of pericardial diseases. *Eur Heart J.* 2015;36(42):2873-2874. doi:10.1093/eurheartj/ehv479

Chiabrando JG, Bonaventura A, Vecchié A, *et al.* Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020;75(1):76-92. doi:10.1016/j.jacc.2019.11.021

Lin D, Laliberté F, Majeski C, *et al*. Disease and economic burden associated with recurrent pericarditis in a privately insured United States population. Adv Ther . 2021;38(10):5127.

Luis SA, LeWinter MM, Magestro M, *et al*. Estimating the U.S. pericarditis prevalence using national health encounter surveillance databases. *Curr Med Res Opin*. 2022;38(8):1385-1389. doi:10.1080/03007995.2022.2070381

Klein A, Cremer P, Kontzias A, *et al*. U.S. Database Study of Clinical Burden and Unmet Need in Recurrent Pericarditis. *J Am Heart Assoc*. 2021;10(15):e018950. doi:10.1161/JAHA.120.018950

Imazio M, Brucato A, Adler Y. A randomized trial of colchicine for acute pericarditis. *N Engl J Med*. 2014;370(8):781. doi:10.1056/NEJMc1315351

Tingle LE, Molina D, Calvert CW. Acute pericarditis. *Am Fam Physician*. 2007;76(10):1509-1514.

Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. *Circulation*. 2014;130(18):1601-1606. doi:10.1161/CIRCULATIONAHA.114.010376

Mody P, Bikdeli B, Wang Y, Imazio M, Krumholz HM. Trends in acute pericarditis hospitalizations and outcomes among the elderly in the USA, 1999-2012. *Eur Heart J Qual Care Clin Outcomes*. 2018;4(2):98-105. doi:10.1093/ehjqcco/qcx040

3. Ammirati E, Cipriani M, Moro C, *et al*. Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry. *Circulation*. 2018;138(11):1088-1099. doi:10.1161/CIRCULATIONAHA.118.035319

Ammirati E, Moslehi JJ. Diagnosis and Treatment of Acute Myocarditis: A Review. *JAMA*. 2023;329(13):1098-1113. doi:10.1001/jama.2023.3371

Basso C. Myocarditis. *N Engl J Med*. 2022; 387(16):1488-1500. doi:10.1056/NEJMra2114478

Bemtgen X, Kaier K, Rilinger J, *et al.* Myocarditis mortality with and without COVID-19: insights from a national

registry. *Clin Res Cardiol*. 2024;113(2):216-222. doi:10.1007/s00392-022-02141-9

Khorolsky, C, Shi, J, Chkhikvadze, T. TRENDS IN HOSPITALIZATION COSTS, LENGTH OF STAY AND COMPLICATIONS AMONG PATIENTS WITH ACUTE MYOCARDITIS: A 10-YEAR UNITED STATES PERSPECTIVE. *J Am Coll Cardiol*. 2019 Mar, 73 (9_Supplement_1) 935.

Lynge TH, Nielsen TS, Gregers Winkel B, Tfelt-Hansen J, Banner J. Sudden cardiac death caused by myocarditis in persons aged 1-49 years: a nationwide study of 14?294 deaths in Denmark. *Forensic Sci Res*. 2019;4(3):247-256. Published 2019 Aug 19. doi:10.1080/20961790.2019.1595352

Tschöpe C, Ammirati E, Bozkurt B, *et al.* Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. *Nat Rev Cardiol*. 2021;18(3):169-193. doi:10.1038/s41569-020-00435-x

Wang X, Bu X, Wei L, Liu J, Yang D, Mann DL, Ma A and Hayashi T (2021) Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017. Front. Cardiovasc. Med. 8:692990. doi: 10.3389/fcvm.2021.692990